SAN DIEGO, Oct. 13, 2026 /PRNewswire/ -- HealthpointCapital, the leading private equity firm focused exclusively on musculoskeletal healthcare, today announced a significant investment in Ospitek, Inc. ("Ospitek" or the "Company"). Founded to address operational inefficiencies across surgical settings, Ospitek's platform delivers real-time visibility across the surgical episode of care, enabling healthcare facilities to optimize operations, enhance communication, and improve patient experiences.
HealthpointCapital Makes Significant Investment in Ospitek, a Leading Provider of Surgical Operations and Patient Flow Intelligence Software
2 min read Premium comments
artificial intelligence#healthpointcapitalOspitekvisibilitydigital infrastructureautomation
Ospitek's technology leverages a combination of artificial intelligence, digital infrastructure, automation, and analytics to synchronize teams, automate communication, and generate real-time operational intelligence. The platform helps healthcare organizations identify inefficiencies, benchmark performance, and make data-driven decisions that improve patient throughput and operating room performance.
"Hospitals and surgery centers are laser-focused on driving efficiency while improving patient, surgeon and staff satisfaction", said Mike Mogul, Managing Partner of HealthpointCapital, "Ospitek gives all of those stakeholders a transparent and informative view of the surgical journey while enabling significant improvements in care delivery capacity for the facility."
Dr. Slim Souissi, Ph.D., Chief Executive Officer of Ospitek, added: " Ospitek's partnership with HealthpointCapital will allow us to accelerate innovation, expand our capabilities, and bring our technology to more surgical facilities across the country. The future of surgery is connected, intelligent, predictive, and patient-centered. And we are excited to help build it."
HealthpointCapital will support continued investment in Ospitek's technology platform, commercial organization, customer success capabilities, and product innovation. The Company is well-positioned to capitalize on the growing demand for workflow automation and operational intelligence solutions across ambulatory surgery centers, specialty hospitals, and broader healthcare settings.
Along with HealthpointCapital's investment in SteriCUBE®, a leading system for surgical equipment flow, Ospitek continues the focus of developing platforms that will enable healthcare facilities, especially ambulatory surgical centers, to scale effectively and efficiently.
Transaction details were not disclosed. McDermott Will & Schulte LLP provided legal counsel to HealthpointCapital.
About HealthpointCapital
HealthpointCapital is the leading private equity firm focused exclusively on the musculoskeletal sector. Led by Managing Partner Mike Mogul together with Matt Link, Milen Todorov, Gary Stevenson, Lisa Holt and Bill Johnson, HealthpointCapital brings together extensive medical device operating experience, a strong private equity track record, and an extensive network of clinical, commercial and strategic company relationships to help portfolio companies accelerate growth. Notable exits for HealthpointCapital include CrossRoads Extremity Systems (acquired by Johnson & Johnson DepuySynthes), OrthoSpace (acquired by Stryker), Blue Belt Technologies (acquired by Smith+Nephew) and BioHorizons (acquired by Henry Schein).
For additional information, visit www.healthpointcapital.com.
About Ospitek, Inc.
Ospitek provides AI- and IoT-powered surgical operations software that delivers real-time visibility across the entire patient journey and helps healthcare providers improve throughput, operating room utilization and patient experience.
For additional information, visit www.ospitek.net.
For investor or media inquiries, please contact: Tessa Cicitta, HealthpointCapital, 212-935-7780 or tcicitta@healthpointcapital.com.
SOURCE HealthpointCapital
Author
TH
TJ Halvorson
The De Angelis Group | Orthopedics This Week | MSK Innovations
Why This Matters
Two Perspectives
MBA Lens: Economic and industry impact
HealthpointCapital, a leading private equity firm in musculoskeletal healthcare, made a significant investment in Ospitek, a provider of surgical operations and patient flow intelligence software. This strategic move aims to address operational inefficiencies, optimize throughput, and enhance patient experiences in surgical settings, particularly ambulatory surgery centers and specialty hospitals, by leveraging AI and automation.
- The investment supports Ospitek's technology platform, commercial organization, and product innovation to capitalize on growing demand for workflow automation.
- HealthpointCapital's portfolio now includes Ospitek and SteriCUBE®, focusing on platforms that enable healthcare facilities to scale effectively and efficiently.
PhD Lens: Clinical and outcomes impact
Ospitek's platform employs a combination of artificial intelligence, digital infrastructure, automation, and analytics to deliver real-time visibility across the surgical episode of care. This technology synchronizes teams and automates communication, enabling healthcare facilities to optimize operations, enhance communication, and improve patient experiences, ultimately boosting patient throughput and operating room performance.
- The system generates real-time operational intelligence, helping organizations identify inefficiencies and benchmark performance for data-driven decisions.
- It aims to improve patient, surgeon, and staff satisfaction by providing a transparent and informative view of the surgical journey.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.